Trials / Completed
CompletedNCT05167864
Evaluation of Four Injectable Neuromodulators in the Glabella Area Glabella Area
A Randomized Prospective Evaluation of Four Injectable Neuromodulators in the Glabella Area
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 143 (actual)
- Sponsor
- University of Pennsylvania · Academic / Other
- Sex
- Female
- Age
- 30 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to use 3D imaging to evaluate the effects of four FDA approved neuromodulators on facial lines, wrinkles and animation. Participation is available to women who have never had a cosmetic procedure above the malar region nor a treatment with a neuromodulator within 12 months. All subjects will undergo 3D imaging using the VECTRA M3 (Canfield Scientific, Inc, Fairfield, NJ) prior to treatment with a neuromodulator in order to determine their baseline dimensions. Imaging will be repeated post injection to determine change over time.
Detailed description
This study is a randomized controlled trial in which patients will be randomly assigned into one of four groups: those receiving onabotulinumtoxinA (Botox, Allergan, Irvine, California), abobotulinumtoxinA (Dysport, Ispen Biopharmacueticals Inc.Cambridge, MA), incobotulinumtoxinA (Xeomin, Raleigh, NC) or prabotulinumtoxinA (Jeuveau, Evolus, Newport Beach, California). Each patient will receive FDA approved dosages in which they are assigned in to treat rhytids within the glabella, as per FDA approved indications. All injections will be performed by a blinded single trained physician according to a preset injection plan per FDA approved administration guidelines. Prior to injection patients will be imaged with 3-dimensional photogrammetry. All pre-procedure images will be evaluated for absolute strain performing two types of facial animation: 1) relaxed, and 2) frowning. Subjects will return Day 3, 30, 90, and 180, post intervention for re-imaging with the same expressions. Strain will be calculated using the same metrics.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Onabotulinumtoxina for Injection | cosmetic injection into the glabella area (eyebrow area) |
| DRUG | Abobotulinumtoxina for Injection | cosmetic injection into the glabella area (eyebrow area) |
| DRUG | IncobotulinumtoxinA for Injection | cosmetic injection into the glabella area (eyebrow area) |
| DRUG | PrabotulinumtoxinA for Injection | cosmetic injection into the glabella area (eyebrow area) |
Timeline
- Start date
- 2022-03-04
- Primary completion
- 2023-06-30
- Completion
- 2023-06-30
- First posted
- 2021-12-22
- Last updated
- 2025-01-17
- Results posted
- 2025-01-17
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05167864. Inclusion in this directory is not an endorsement.